The life science group Sartorius has successfully closed the acquisition of MatTek Corp, including Visikol Inc, from the Swedish BICO Group AB, as announced in April. The acquisition was completed on July 1, 2025, following the receipt of the required regulatory approval and the fulfillment of other customary closing conditions. With the integration of the business into its Lab Products and Services division, Sartorius is expanding its cell technology portfolio and creating synergies with existing solutions for drug development, including cell analysis instruments, reagents, and AI models.

MatTek is a leading developer and manufacturer of human cell-based microtissues and 3D models that accelerate drug development. The advanced cell models mimic the structure and function of human tissue and deliver more accurate, cost-effective, and reproducible results compared to traditional 2D cell cultures, while reducing the need for animal testing. The company employs more than 80 people at its headquarters in Ashland, Massachusetts, USA, and at its production site in Bratislava, Slovakia.